Summary of Key Information:

Reporting Period (Quarter/Year): Quarter ended 30th June, 2026 (Q1 FY27)

Nature of Filing / Announcement: Submission of Unaudited Financial Results to Stock Exchanges

Audit Opinion:

The Limited Review Report by the Statutory Auditors, C N K & Associates LLP, did not modify their opinion. However, they included an 'Emphasis of Matter' paragraph.

Auditor’s Comment:

The auditors emphasized a disputed liability related to pending electricity duty. An aggregate provision of ₹2,052.13 lakhs has been made for the principal amount. The interest is not ascertainable and is disclosed as a contingent liability. The company has deposited ₹35 Crores with the Supreme Court, and its appeal has been admitted.

Key Financial Highlights [All figures in ₹ Lakhs]

Consolidated Results:

Revenue from Operations: 4,975 (Unaudited for Q1 FY27)

Other Income: 359

Total Income: 5,334

Net Profit/(Loss) after tax and Share of Associate's Profit/(Loss): 6,489

This represents an increase from ₹6,164 lakhs in the prior year quarter (Q1 FY26).

Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.): 2.53

Share of Associate's Profit/(Loss): 4,919

Other Comprehensive Income/(Loss): 6,371

Total Comprehensive Income/(Loss) for the Period: 12,860

Paid up Equity Share Capital: 5,135.64

Standalone Results:

Revenue from Operations: 4,627 (Unaudited for Q1 FY27)

Other Income: 555

Total Income: 5,182

Net Profit after tax for the Period: 1,468

This represents a decrease from ₹1,712 lakhs in the prior year quarter (Q1 FY26).

Other Comprehensive Income/(Loss): 6,306

Total Comprehensive Income/(Loss) for the Period: 7,774

Paid up Equity Share Capital: 5,135.64

Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.): 0.57

Segment-wise Performance [All figures in ₹ Lakhs]:

Consolidated Segment Revenue (from Operations):

Not explicitly stated in a single table cell for the current quarter. The standalone segment revenue is provided.

Consolidated Segment Results (Profit/(Loss) before Taxes and Interest):

a. Active Pharmaceutical Ingredients Business: 166

b. Real Estate Business: 1,398

Total: 1,564

Standalone Segment Revenue (from Operations):

a. Active Pharmaceutical Ingredients Business: 1,171

b. Real Estate Business: 3,455

Total Income from Operations (Net): 4,627

Standalone Segment Results (Profit/(Loss) before Taxes and Interest):

a. Active Pharmaceutical Ingredients Business: 166

b. Real Estate Business: 1,224

Total: 1,391

Corporate Actions:

Not Specified

Other Significant Information:

Not Specified